SG Americas Securities
TRAW icon

SG Americas Securities’s Traws Pharma TRAW Stock Holding History

SG Americas Securities’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Buy
+14,524
New +$20K ﹤0.01% 3289

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SG Americas Securities's TRAW Position: Q2 2026 in Review

SG Americas Securities opened a new position in Traws Pharma (TRAW) in Q2 2026: 14,524 shares worth $12K. The stake represents ﹤0.01% of the portfolio and ranks #3289 among its holdings.

21 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

  • SG Americas Securities held 14,524 shares of Traws Pharma worth $12K as of Q2 2026.
  • Traws Pharma was a new SG Americas Securities position in Q2 2026.
  • Traws Pharma made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #3289 holding.
  • 21 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.